Sanofi to pay Regeneron up to $8 billion to expand Dupixent antibody pipeline

Sanofi said it will pay Regeneron up to $8 billion to add new antibody candidates under their Dupixent partnership, an arrangement that has already produced one of the industry's top-selling drugs for conditions like eczema and asthma. Sanofi shares rallied following the announcement. The deal extends a collaboration that has proven lucrative for both companies, giving Sanofi access to Regeneron's antibody research pipeline beyond the current Dupixent franchise. For Sanofi, it signals a bet on expanding beyond its existing blockbuster rather than relying solely on patent-protected sales of the current drug. The terms suggest the payments are tied to milestones rather than a single upfront sum, though the wire reports do not specify the staging or what triggers each tranche.